Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Extends Push Into Oncology With Agenus R&D Pact

Executive Summary

Allying itself with US biotech Agenus underscores Gilead's oncology ambitions, which incoming CEO-designate Daniel O'Day must make good on.

Advertisement

Related Content

Deal Watch: Cancer Remains Hot Target At J.P. Morgan
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
Top 20 Pharma Ranks: As Some Move Up, Others Fall Down
What's Gilead Getting From Kite For Nearly $12bn?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel